^
    Back
    Association details:
    Biomarker:GIMAP6 overexpression
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Immunol Cell Biol
    Title:

    Investigation and verification of GAMAP6 as a robust biomarker for prognosis and tumor immunity in lung adenocarcinoma

    Published date:
    02/05/2023
    Excerpt:
    The OS and DSS of lung adenocarcinoma patients with high GIMAP6 expression was better than that with low GIMAP6 expression.
    DOI:
    10.22541/au.167564011.11404549/v1